gsk partners with chimagen for lupus drug deal worth up to 850 million

GSK Plc has made a significant agreement with Chimagen Biosciences, a Chinese biotech firm, to acquire an experimental drug for expanding its lupus treatment pipeline.

The deal involves an upfront payment of $300 million, with the potential for Chimagen to receive an additional $550 million based on the drug's success.

The antibody drug, currently in early clinical trials for leukemia and lymphoma, is expected to begin early trials for lupus in 2025.

This acquisition highlights GSK's dedication to developing innovative therapies for autoimmune diseases.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings